In our models of RMS, tipifarnib selectively inhibited tumor growth in HRAS-mutant xenografts early in the treatment course and without toxicity, consistent with other mouse models of HRAS-mutant cancers [32, 33, 56]. This evidence concerns the gene HRAS and neoplasm.